Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBioSTU:83B +1.64%88 5-Year Yield-on-Cost % is 1.53 as of Jul. 31, 2026, which is 1% below its 10-year median of 1.55. GuruFocus rates STU:83B with a GF Score™ of 88/100 and a GF Value™ of €1.46 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, 3SBio ranks worse than 54% on this metric.
3SBio's yield on cost for the quarter that ended in Dec. 2025 was 1.53.
The historical rank and industry rank for 3SBio's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:83B'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.42 Med: 1.55 Max: 4.36
Current: 1.53
During the past 12 years, 3SBio's highest Yield on Cost was 4.36. The lowest was 0.42. And the median was 1.55.
STU:83B's 5-Year Yield-on-Cost % is ranked worse than 54% of 150
companies
in the Biotechnology industry
Industry Median: 1.71
vs STU:83B: 1.53
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
3SBio 5-Year Yield-on-Cost % Related Terms
STU:83B vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, 3SBio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where 3SBio's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of 3SBio is calculated as
3SBio (STU:83B) has a 5-Year Yield-on-Cost % of 1.53 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on 3SBio and its competitors. This is near median its historical median of 1.55. Over the past decade, 3SBio's 5-Year Yield-on-Cost % has ranged from 0.42 to 4.36. According to the industry distribution chart, 3SBio ranks #81 out of 150 companies in the Biotechnology industry, placing it in the top 54%.
Is 3SBio's 5-Year Yield-on-Cost % too high?
3SBio's current 5-Year Yield-on-Cost % of 1.53 is near median its 10-year median of 1.55. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 4.36. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.71. 3SBio's value of 1.53 is 10.5% below this industry median. Based on the distribution chart, 3SBio ranks #81 out of 150 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 3SBio has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #81 out of 150 companies for 5-Year Yield-on-Cost %. This places 3SBio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.71. 3SBio's value of 1.53 is 10.5% below this benchmark. Historically, 3SBio's own 5-Year Yield-on-Cost % has ranged from 0.42 to 4.36 over the past decade. While the company's 10-year median is 1.55 vs. the industry median of 1.71, 3SBio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.71, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current 5-Year Yield-on-Cost % of 1.53 is 10.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current 5-Year Yield-on-Cost % is 1.53, which is near median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.46, compared to a current price of €1.86 — trading 27.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.53, which is near median its 10-year median of 1.55 and 10.5% below the Biotechnology industry median of 1.71. 3SBio's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For 3SBio (STU:83B), the current 5-Year Yield-on-Cost % is 1.53 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.86 is trading 27.4% above its estimated GF Value™ of €1.46.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
5-Year Yield-on-Cost %: 1.53 (near median its 10-year median of 1.55)
GF Value™: €1.46 vs. price of €1.86 (27.4% above fair value)
Industry Position: 10.5% below the Biotechnology median (#81 of 150)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
88GF Score
Get the complete analysis for STU:83B
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
